"mers-cov"

The platform is based on a beta-propiolactone (BPL)-inactivated, whole-virus approach - a modernised take on traditional vaccine technology, according to the NIH on Thursday.

Researchers explore possibility of utilising antiserum derived from the animals as a therapeutic in Covid treatment